What is the appropriate initial testosterone regimen for a transgender male, including dose, route, baseline labs, and monitoring?

Initial Testosterone Therapy for Transgender Males

For transgender males initiating testosterone therapy, start with intramuscular testosterone cypionate or enanthate at 50-100 mg every 1-2 weeks (or 25 mg weekly subcutaneously), titrating upward over 6-12 months to achieve mid-normal male testosterone levels (300-700 ng/dL), with baseline labs including CBC, comprehensive metabolic panel, lipids, and testosterone/estradiol levels. 1

Testosterone Formulation and Dosing

The most commonly used and evidence-based approach is intramuscular testosterone esters (cypionate or enanthate). 2 The Endocrine Society guideline for transgender care provides specific monitoring protocols adapted from hypogonadal male treatment. 1

Initial Dosing Strategies

Two validated approaches exist:

Conservative titration protocol (preferred for minimizing adverse effects):

• Start: 25 mg IM monthly
• Month 3: Increase to 50 mg monthly
• Month 6: Increase to 100 mg monthly
• Month 9: Increase to 250 mg monthly 3

This approach demonstrated excellent gender congruence (70-80% satisfaction) with minimal hematocrit elevation and no significant lipid changes. 3

Standard protocol (faster virilization):

• Start: 50-100 mg IM every 1-2 weeks
• Adjust based on testosterone levels and clinical response 1, 2
• Alternative: 250 mg every 2-3 weeks for more rapid effects 4

Subcutaneous alternative: 50 mg weekly self-administered subcutaneously achieved target levels in 81% of patients with excellent safety profile. 5

Route Selection

• Intramuscular (deep gluteal): Most evidence-based, FDA-approved route 6
• Subcutaneous: Emerging evidence supports weekly 50 mg dosing with comparable efficacy and improved convenience 5
• Transdermal gels: Less commonly used in transgender care; require skin-to-skin contact precautions 7

Baseline Laboratory Evaluation

Obtain before initiating therapy:

• Complete blood count (baseline hematocrit critical) 7, 1
• Comprehensive metabolic panel (liver function, glucose) 1
• Lipid panel 1
• Testosterone (total and free) 1
• Estradiol 1
• Consider: Hemoglobin A1c if diabetic or family history 1

Contraindications to assess:

• Hematocrit >50% is a relative contraindication (many will exceed 54% on therapy) 7
• Active cardiovascular disease requires careful risk assessment 1

Monitoring Protocol

Testosterone Level Monitoring

Timing is formulation-specific and critical for interpretation:

• Injectable testosterone enanthate/cypionate: Measure midway between injections at 2-3 months, then adjust 7, 1

  • Target: 400-700 ng/dL (mid-normal male range)
  • If >700 ng/dL: Reduce dose or increase interval
  • If <400 ng/dL: Increase dose or decrease interval 7

• Subcutaneous weekly: Can measure anytime after 1 week of steady dosing 1

Clinical and Laboratory Follow-up

First year (intensive monitoring):

• Visits: Every 2-3 months 1, 2
• Labs at each visit:
  • Testosterone level (timing per above)
  • Hematocrit (critical safety parameter)
  • Liver function tests
  • Lipids

After first year:

• Visits: Every 6-12 months 1, 2
• Continue monitoring hematocrit, testosterone, metabolic parameters

Estradiol Monitoring

• Check during first 6 months or until menses cease 1
• Target: <50 pg/mL 1, 5
• 68-78% achieve target suppression with standard dosing 3, 5

Safety Monitoring: Critical Thresholds

Hematocrit Management (Most Important Safety Parameter)

If hematocrit >54%:

1. Stop testosterone immediately 7, 1
2. Evaluate for hypoxia and sleep apnea 7, 1
3. Wait until hematocrit decreases to safe level
4. Reinitiate at reduced dose 7, 1

This is non-negotiable—polycythemia increases thrombotic risk and represents the most common dose-limiting toxicity.

Cardiovascular Risk Factors

Monitor at each visit:

• Blood pressure (may increase modestly) 1, 8
• Weight and BMI 1
• Lipids: Expect HDL decrease, triglyceride increase 8
• Fasting glucose/HbA1c if indicated 1
• Consider plasma atherogenic index (PAI) and triglyceride-glucose (TyG) index for early cardiometabolic changes 8

Expected Timeline of Effects

Understanding this helps set realistic expectations:

Within 1-3 months:

• Cessation of menses (78-91% of patients) 9, 5
• Voice deepening begins (87% by 6 months) 9
• Acne (69% within 3 months) 9
• Increased libido 9

3-6 months:

• Facial hair growth (53%) 9
• Body hair growth (38%) 9
• Most physical changes evident 2, 4

Maximum virilization: 3-5 years of regular use 2

Dose-response relationship: Higher initial doses produce faster onset but similar 6-month outcomes compared to lower doses 4. This supports starting conservatively.

Common Pitfalls and Caveats

1. Timing of testosterone measurement matters critically: Measuring at trough vs. peak can show 2-3 fold differences. Always document injection timing relative to blood draw. 10

2. SHBG effects: During first 3-9 months, total testosterone may appear high while free testosterone is normal due to elevated SHBG in biological females. 1 Don't over-adjust dose based on total testosterone alone.

3. Symptom cycling with longer intervals: If using every-2-week dosing and patient reports mood swings, acne, or late-cycle fatigue, consider more frequent lower doses (weekly or twice-weekly) rather than increasing total dose. 10

4. Cervical cancer screening: If cervix present, continue annual Pap smears per standard guidelines. 1

5. Breast tissue: If mastectomy not performed, continue mammogram screening per standard guidelines. 1

6. Bone density: Consider baseline DEXA if risk factors present; otherwise screen at age 60 or if non-compliant with therapy. 1

Practical Algorithm

1. Confirm diagnosis with mental health professional involvement
2. Baseline labs: CBC, CMP, lipids, testosterone, estradiol
3. Exclude contraindications: Hematocrit >50%, unstable cardiovascular disease
4. Choose regimen:
   • Conservative: Start 25-50 mg IM monthly, titrate over 9 months
   • Standard: 50-100 mg IM every 1-2 weeks
   • Alternative: 50 mg subcutaneous weekly
5. Monitor testosterone at 2-3 months (midway between injections for IM)
6. Adjust to achieve 400-700 ng/dL and estradiol <50 pg/mL
7. Check hematocrit at 3,6,12 months—stop if >54%
8. Transition to 6-12 month monitoring after first year

The evidence strongly supports that testosterone therapy is safe and effective when properly monitored, with the conservative titration approach offering the best balance of efficacy and safety for most patients. 3, 11